Tumour markers for managing men who present with metastatic prostate cancer and serum prostate‐specific antigen levels of <10 ng/mL
Authors:
- John R.W. MastersJMJohn R.W. Masters
- Contributors To The Baus Section Of Oncology Cancer RegistryCRContributors To The Baus Section Of Oncology Cancer Registry
- 24 July 2005
- journal article
- Published by Wiley in BJU International
- Vol. 96 (3) , 303-307
Abstract
OBJECTIVE: To define immunohistochemical features of the primary cancers that might help in the differential diagnosis and monitoring of treatment in men presenting with metastatic prostate cancer and low serum levels of prostate‐specific antigen (PSA), who can be difficult to diagnose and manage. PATIENTS AND METHODS: Paraffin blocks of prostate biopsies were obtained for 33 patients presenting with untreated metastatic prostate cancer and serum PSA levels of <10 ng/mL. Sections were immunostained for PSA, prostatic acid phosphatase (PAP), prostate‐specific membrane antigen (PSMA), androgen receptor (AR), chromogranin A and CD 56. RESULTS: The combined Gleason scores were 8–10 in 25 men (76%) and 6 or 7 in the other eight (24%). Morphologically, there were no neuroendocrine features. PSA immunostaining was equivocal in 12 (36%) cases and in a further 19 (58%) was strong but focal and could be missed on biopsy sampling. PSMA was expressed in 90% of cases, and staining was widely distributed in nine of the 12 in which PSA staining was equivocal. There was strong AR expression in 30 (91%) cases and it was present in areas where PSA was absent. CONCLUSION: In this patient group, immunohistochemical assessments of PSMA and AR are potentially useful as diagnostic markers.Keywords
This publication has 20 references indexed in Scilit:
- Prostate cancer screeningBJU International, 2004
- Prostate‐specific antigen testing for the early detection of prostate cancerBJU International, 2004
- Clinical features of patients who present with metastatic prostate carcinoma and serum prostate‐specific antigen (PSA) levels < 10 ng/mLCancer, 2003
- High molecular weight cytokeratin antibody (clone 34βE12): a sensitive marker for differentiation of high‐grade invasive urothelial carcinoma from prostate cancerHistopathology, 2003
- M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mLInternational Journal of Urology, 2001
- Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinomaUrology, 2001
- Prostate Specific Antigen and Gleason Grade: An Immunohistochemical Study of Prostate CancerJournal of Urology, 1994
- Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostateBritish Journal of Radiology, 1994
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987
- THE UNLABELED ANTIBODY ENZYME METHOD OF IMMUNOHISTOCHEMISTRY PREPARATION AND PROPERTIES OF SOLUBLE ANTIGEN-ANTIBODY COMPLEX (HORSERADISH PEROXIDASE-ANTIHORSERADISH PEROXIDASE) AND ITS USE IN IDENTIFICATION OF SPIROCHETESJournal of Histochemistry & Cytochemistry, 1970